E. Solsona

Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

J.A. Martínez‐Pin ̃eiro, N Flores, Santiago Isorna et al. · British Journal of Urology · 2002 · 211 citations

PROSPECTIVE VALIDATION OF THE ASSOCIATION OF LOCAL TUMOR STAGE AND GRADE AS A PREDICTIVE FACTOR FOR OCCULT LYMPH NODE MICROMETASTASIS IN PATIENTS WITH PENILE CARCINOMA AND CLINICALLY NEGATIVE INGUINAL LYMPH NODES

E. Solsona, I. Iborra, José Rubio et al. · The Journal of Urology · 2001 · 207 citations

EFFECTIVENESS OF A SINGLE IMMEDIATE MITOMYCIN C INSTILLATION IN PATIENTS WITH LOW RISK SUPERFICIAL BLADDER CANCER: SHORT AND LONG-TERM FOLLOWUP

E. Solsona, J.V. Ricós, J.L. Monrós et al. · The Journal of Urology · 1999 · 189 citations

THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCER

E. Solsona, I. Iborra, R. Dumont et al. · The Journal of Urology · 2000 · 188 citations

Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

Luis Paz‐Ares, E. Solsona, Emilio Esteban et al. · Journal of Clinical Oncology · 2010 · 164 citations

Urological Research, Urology, Surgical Oncology +14